Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome from Non-Controlling InterestsIncome towards Parent CompanyInterest ExpensesNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Albemarle (ALB-PA) Research & Development (2016 - 2025)

Albemarle's Research & Development history spans 17 years, with the latest figure at $12.4 million for Q2 2025.

  • For Q2 2025, Research & Development fell 40.09% year-over-year to $12.4 million; the TTM value through Jun 2025 reached $69.0 million, down 21.76%, while the annual FY2025 figure was $51.4 million, 40.73% down from the prior year.
  • Research & Development reached $12.4 million in Q2 2025 per ALB-PA's latest filing, down from $14.1 million in the prior quarter.
  • In the past five years, Research & Development ranged from a high of $23.5 million in Q1 2024 to a low of $12.1 million in Q4 2021.
  • Average Research & Development over 5 years is $18.1 million, with a median of $19.2 million recorded in 2022.
  • Peak YoY movement for Research & Development: skyrocketed 66.22% in 2022, then plummeted 40.09% in 2025.
  • A 5-year view of Research & Development shows it stood at $12.1 million in 2021, then soared by 66.22% to $20.2 million in 2022, then increased by 12.9% to $22.8 million in 2023, then fell by 12.01% to $20.0 million in 2024, then crashed by 37.85% to $12.4 million in 2025.
  • Per Business Quant, the three most recent readings for ALB-PA's Research & Development are $12.4 million (Q2 2025), $14.1 million (Q1 2025), and $20.0 million (Q4 2024).